Morgan Stanley analyst Michael Ulz maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $120.00. The company’s shares closed yesterday at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback